New phase 3 and 4 trials on ClinicalTrials.gov reach 104, against a median of 80

PostNewz's weekly count of the ClinicalTrials.gov register found 104 new phase 3 and phase 4 trial registrations dated in the week of Monday Oct. 26 through Sunday Nov. 1, 2026. The comparison point is a median of 80 registrations a week across the 18 complete weeks before that week.

Phase 3 trials test an experimental treatment in people at a scale meant to show whether it works; phase 4 trials are run after a treatment is approved. A registration is a public filing of a study's plan, not a finding. Under 42 CFR Part 11, an applicable clinical trial is to be registered no later than 21 calendar days after the first participant is enrolled.

Registrations dated Oct. 30, 2026, in the count include NCT07908082, a study of aspirin for the prevention of ischemic complications in giant cell arteritis sponsored by the Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal; NCT07906275, an intra-arterial treatment study within the ACT-GLOBAL adaptive platform trial sponsored by the University of Calgary; and NCT07907991, the AIRWARD study of verducatib in chronic obstructive pulmonary disease sponsored by Boehringer Ingelheim.

PostNewz's check of how unusual the week is compares it with the 17 earlier complete weeks in the same series, where the median was 77 and the week-to-week spread was typically about 8 registrations. The week of Oct. 26 ranks at the 100th percentile of those weeks and sits 3.4 typical spreads above that median.

The count is of registrations, not of completed or published studies, and says nothing about whether any listed trial will produce a result. The register itself is the source for every figure here.

Room for disagreement

One week is a short window, and 104 is compared with a median rather than with any single earlier week; the same series includes weeks of 53 and 60 registrations in October. A single week's total may not reflect the level in later weeks.